Evidence map›Paper›PMID 35251693›Full record

ArticleFuture science OA2022

Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetes.

Anna A Mosikian, Tatiana I Golikova, Mariia V Martjanova, Alina Y Babenko

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future science OA, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Anna A MosikianInstitute of Endocrinology, Laboratory of Diabetology, World-Class Research Centre for Personalized Medicine, Almazov National Medical Research Centre, Saint Petersburg, Russia.
Tatiana I GolikovaInstitute of Endocrinology, Laboratory of Diabetology, World-Class Research Centre for Personalized Medicine, Almazov National Medical Research Centre, Saint Petersburg, Russia.
Mariia V MartjanovaInstitute of Endocrinology, Laboratory of Diabetology, World-Class Research Centre for Personalized Medicine, Almazov National Medical Research Centre, Saint Petersburg, Russia.ORCID https://orcid.org/0000-0002-1414-0034
Alina Y BabenkoInstitute of Endocrinology, Laboratory of Diabetology, World-Class Research Centre for Personalized Medicine, Almazov National Medical Research Centre, Saint Petersburg, Russia.
Federal Almazov North-West Medical Research Centre · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe effects of liraglutide on body weight and hemoglobin A1C (HbA1c) level vary greatly. The cost of this drug negatively affects treatment adherence.

aimTo reveal the baseline patient characteristics, associated with a better response to liraglutide. MATERIALS AND

methodsA total of 41 patients with BMI of 39.63 ± 7.59 kg/m

resultsWeight reduction was dose-dependent (p = 0.007). Liraglutide was not effective in patients with BMI >45 kg/m

conclusionDrug-specific efficacy predictors were assumed; thus, further studies are needed to prove their significance.

Indexed as

diabetes mellitusglucagon-like peptide-1 receptor agonistsliraglutideobesitypredictors

Identifiers

PMID35251693
PMCPMC8890266
OpenAlexW4210815697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.